INFORMATION FOR SUBMITTERS

  • The CGC 2026 Annual Meeting will be held on August 1-5, 2026, at the Royal Sonesta Houston Galleria, Houston, TX, USA.
  • Abstracts are selected based on scientific merit.
  • The body of the abstract should not exceed 450 words, and abstracts should be formatted to follow the structure described below in the Abstract Submission Instructions. 
  • Submissions to the “Case Studies” topic should include case presentations involving one or two clinical cases.

IMPORTANT DATES

  • March 3, 2026  Abstracts submission deadline (11:59 pm Pacific Time)

  • April 10, 2026  Anticipated date of acceptance notification emails 

  • April 21, 2026  Deadline for presenting authors of accepted abstracts to register and pay for meeting attendance

  • June 19, 2026  Deadline for submission of slide presentations for platform presentations for CME review of content. Additional details will be sent to platform presenters with their acceptance notifications. 

  • July 9, 2026  Deadline for submission of poster PDF for poster presentations and inclusion in virtual poster session on the CGC 2026 Virtual Platform, which will be available to all participants. Additional details will be sent to poster presenters with their acceptance notifications.

ABSTRACT SUBMISSION INSTRUCTIONS

  • CGC Membership is not required to submit an abstract. If you are not a current CGC member, simply select the option to submit "without logging in" when entering the abstract submission portal. We hope you will consider membership in the future.
  • Abstracts should represent original scientific research, and the body of the abstract should be limited to a maximum of 450 words.
  • Abstract submission is open for both Oncology and Constitutional topics. Suggested topics are listed below with descriptions; however, abstracts outside these topics will also be considered.
  • Scientific abstracts should be structured into:
    • Introduction: Provides context and explains the problem or research question being addressed.
    • Methods: Outlines the study design, research procedures, and techniques used.
    • Results: Presents the key findings of the study in a clear and concise manner.
    • Discussion and Conclusion: Interprets the results, highlighting the study’s significance and implications
  • Case Study abstracts should be structured into:
    • Introduction: Emphasizes the significance or rarity of the case.
    • Case Presentation: Details the patient’s symptoms, history, and any relevant factors.
    • Diagnostic Workup and Management: Describes the diagnostic process, tests performed, and any unusual findings. In addition, discusses the care provided, including any experimental treatments.
    • Discussion and Conclusion: Explores the implications of the case, comparing it with existing literature or similar cases, and summarizes key insights and suggests areas for future research.
  • While in the submission module, if you need to return to a previous page in the submission process, please use the back arrow on your browser.
  • If the submitting author is not the presenting author, please provide the presenting author’s full name, affiliation, email address, and phone number in the designated section of the submission process.
  • Submitting and presenting authors must complete a Conflict of Financial Interest Form upon submission of each abstract.
  • Abstracts should avoid self-promotion and focus on rigorous, data-driven conclusions without embellishment. Case presentations should provide an overview of the symptoms, diagnosis, treatment, and follow-up of the patient, especially for unique or rare cases.
  • Trainees and technologists are eligible to apply for travel grants.
  • Once an abstract is accepted, registration for the meeting will be required for participation.
  • Accepted abstracts will be selected for either a “Platform” or “Poster” presentation. 
  • If you have challenges with your submission, please email meetings@cancergenomics.org.

2026 ABSTRACT TOPICS

  1. Hematologic Malignancies
  2. Solid Tumors
  3. Germline/Constitutional Genomics and Mosaicism (including Cancer Predisposition Risk Factors, Somatic Mosaic Disorders, etc.)
  4. Bioinformatics, Artificial Intelligence/Machine-Learning, Lab Automation
  5. Variant Curation, Interpretation, and Standardization
  6. Emerging Technologies and other advances in Clinical Genomics (including Liquid Biopsies, cell-free DNA, Single-Cell analyses, Epigenetics, Transcriptomics, Multi-Omics, etc.)
  7. Equity and Access in Genomic Medicine (including Genomic Test Implementation in Resource-Limited Countries, Access to Technical Expertise, etc.)
  8. Ethical and Regulatory Considerations in Genomic Testing
  9. Other Advances (technical, quality improvement, education, laboratory management)
  10. Case Studies
  11. Cancer Genetic Counseling
  12. Therapeutics/Pharmacogenomics/Precision medicine
  13. Other

ABSTRACT TOPIC DESCRIPTIONS

1. Hematologic Malignancies
Including but not limited to the discovery, development, and application of biomarkers and genomics for improving the diagnosis or prognosis of hematologic malignancies and clonal hematopoiesis (CHIP, CCUS). Topics may include diagnostic work-up and testing algorithms, practice guidelines, genomic applications in updated diagnostic classifications prognostication (e.g., WHO, ICC, NCCN), and molecular diagnostic tools for the detection of measurable residual disease (MRD). Additional areas may include clinical correlations, risk factors, and other aspects of disease biology, including preclinical and mechanistic studies focused on novel biomarker development.

2. Solid Tumors
Including but not limited to the discovery, development, and application of biomarkers and genomics for improving the diagnosis or prognosis of solid tumors. Topics may cover diagnostic work-up and testing algorithms, practice guidelines, genomic applications in updated diagnostic criteria, prognostication, molecular diagnostic tools for measurable residual disease (MRD) detection, tumor mutational burden (TMB), and genotype-outcome correlations. Additional areas may include clinical correlations, risk factors, and other aspects of disease biology, including preclinical and mechanistic studies focused on novel biomarker development.

3. Germline/Constitutional Genomics and Mosaicism (including Cancer Predisposition Risk Factors, Somatic Mosaic Disorders, etc.)
Including but not limited to new discoveries in diagnosis and detection approaches, genotype-phenotype correlations, clinical findings, and incidental findings of clinical significance during routine testing. Topics may also cover polygenic risk scores, hereditary cancer syndromes, cancer predisposition, new candidate genes, vascular anomalies, tissue overgrowth syndromes, and inherited cardiomyopathies. 

4. Bioinformatics, Artificial Intelligence, and Machine-Learning
Including but not limited to the development, exploration, and integration of computational methodologies and machine learning algorithms for the analysis and interpretation of data to improve diagnostics and therapeutics, and innovations in automation within both wet and dry lab processes as they pertain to genomic assays. Topics may include novel applications in research and clinical laboratories, applications in drug interaction and development, electronic health records (EHR), integration and reporting of genomic data in EHR, challenges in bioinformatics, computer-aided decision-making, automation or technical advancements in the management and sharing of genomic-scale data, as well as the impact of automation on efficiency, accuracy, and scalability in genomic research and clinical laboratory applications.

5. Variant Curation, Interpretation, and Standardization
Including but not limited to innovative methodologies, knowledgebase searches, computational resources, and best practices for accurately assessing genomic variants in both somatic and germline conditions. Topics may also highlight efforts to standardize variant annotation and reporting where possible.

6. Emerging Technologies and other advances in Clinical Genomics (including Liquid Biopsies, cell-free DNA, Single-Cell analyses, Epigenetics, Transcriptomics, Multi-Omics, etc.):
Including but not limited to whole genome, exome, and targeted sequencing, optical genome mapping, long-read DNA/RNA technologies, spatial transcriptomics, methylation sequencing, liquid biopsies, cell-free DNA analysis, proteomics, cytometry by time-of-flight (cyTOF), metabolomics, and other omics. 

7. Equity and Access in Genomic Medicine (including Genomic Test Implementation in Resource Limited Countries, Access to Technical Expertise, etc.)
Including but not limited to challenges and solutions for implementing genomic testing in resource-limited settings, addressing disparities in access to genomic technologies, increasing representation in genomic databases, and enhancing access to technical expertise and training. Topics may include efforts to increase diversity in genomics research and strategies to improve equitable access to genomic medicine.

8. Ethical and Regulatory Considerations in Genomic Testing
Including but not limited to guidelines and regulatory compliance, economic aspects such as billing, coding, and reimbursement, resource utilization, and social and ethical considerations in genomic testing. Topics may also cover challenges in reporting, workflow optimization, data privacy, and the ethical implications of genomic testing and data sharing.

9. Other Advances (technical, quality improvement, education, laboratory management):
Advances not otherwise included by other topics that relate to clinical laboratory function and performance. Topics may include but are not limited to quality improvement projects and measures, innovative educational advances in genetics, laboratory management applications and innovations.

10. Case Studies 
Case presentations must describe the genetic/genomic methods used and provide relevant clinical data to support the diagnosis in question. Emphasis should be placed on the diagnostic challenge and unique insights gained from the cases. Cases submitted under this topic will be considered for brief, daily pre-meeting agenda presentations. Cases not selected for a presentation in the CGC 2026 Annual Meeting may be considered for future CGC webinars. 

11. Cancer genetic counseling
Including but not limited to aspects of genetic counseling in the cancer realm, and its associated successes and challenges. Submissions in this category may cover topics such as patient interactions, patient distress levels, interpretation challenges, NGS gene panel complexity and challenges, screening-related issues, insurance/employment/out-of-pocket cost-related topics, privacy issues, and familial implications.

12. Therapeutics/Pharmacogenomics/Precision medicine
Including but not limited to genetic and therapeutic influences of drug metabolizer status with a focus on oncology, clinical trial results, novel gene/chromosomal alterations and outcomes, immunotherapy. Abstracts may also address these topics in fields other than cancer. 
 
ACCEPTED ABSTRACTS 
  • Platform abstracts will be assigned a session date and time to be orally presented. Platform presenters will be required to begin presentations with a slide disclosing any financial interest of any dollar amount or state no conflicts if none exists.
  • Abstracts accepted as a Poster are to be displayed in printed format in the exhibit hall during one of the two Poster Sessions. Poster size is three feet (3’) wide by four feet (4’) tall (portrait orientation).
  • All presentations should be balanced, transparent, and supported by data.

COMMERCIAL NATURE/INELIGIBLE COMPANIES 

  • The abstract submission process includes an attestation that the abstract is not commercial in nature. Abstracts are expected to be fair and balanced in their presentations. 
  • Abstracts commercial in nature, exhibiting self-promotion, or submitted by ineligible companies (as defined by the ACCME) will not be accepted. Please see our abstract web page for additional details.
  • Companies who choose to support the meeting have other opportunities to present data about specific products, including the Industry Poster Session, which is only available to those companies supporting the CGC Annual Meeting.